Suppression of VEGFR2 Expression in Human Endothelial Cells by Dimethylfumarate Treatment: Evidence for Anti-Angiogenic Action (Q54601626)

1 June 2018

title

Suppression of VEGFR2 Expression in Human Endothelial Cells by Dimethylfumarate Treatment: Evidence for Anti-Angiogenic Action (English)

1 reference

28 November 2024

main subject

endothelium

0 references

angiogenesis inhibitor

1 reference

2

Monika Doll

1 reference

1 June 2018

Roland Kaufmann

8

Roland Kaufmann

1 reference

1 June 2018

Jens Gille

7

Jens Gille

1 reference

1 June 2018

Igor Hrgovic

3

Igor Hrgovic

1 reference

1 June 2018

Gabi Reichenbach

4

Gabi Reichenbach

1 reference

1 June 2018

Tsige Hailemariam-Jahn

6

Tsige Hailemariam-Jahn

1 reference

1 June 2018

Markus Meissner

1

Markus Meissner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21430706

28 November 2024

author name string

Veronika König

5

1 reference

1 June 2018

language of work or name

English

0 references

publication date

24 March 2011

1 reference

1 June 2018

full work available at URL

http://www.jidonline.org/article/S0022202X15352775/pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21430706

https://api.elsevier.com/content/article/PII:S0022202X15352775?httpAccept=text/xml

28 November 2024

1 reference

https://api.elsevier.com/content/article/PII:S0022202X15352775?httpAccept=text/plain

28 November 2024

1 reference

Journal of Investigative Dermatology

28 November 2024

published in

1 reference

1 June 2018

volume

131

1 reference

1 June 2018

issue

6

1 reference

1 June 2018

page(s)

1356-1364

1 reference

1 June 2018

Positive and negative modulation of angiogenesis by VEGFR1 ligands

cites work

1 reference

7 January 2021

Angiogenesis in cancer and other diseases

1 reference

7 January 2021

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

7 January 2021

Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect.

1 reference

7 January 2021

Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.

1 reference

7 January 2021

Angiogenesis drives psoriasis pathogenesis

1 reference

7 January 2021

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

7 January 2021

Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner

1 reference

7 January 2021

Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells

1 reference

7 January 2021

Dimethylfumarate impairs melanoma growth and metastasis

1 reference

7 January 2021

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

1 reference

7 January 2021

Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanisms

1 reference

7 January 2021

Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells.

1 reference

7 January 2021

VEGF receptor signalling - in control of vascular function

1 reference

7 January 2021

The vasculature in rheumatoid arthritis: cause or consequence?

1 reference

7 January 2021

Angiogenesis in inflammatory bowel disease.

1 reference

7 January 2021

The discovery of antiangiogenic molecules: a historical review

1 reference

7 January 2021

Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression

1 reference

7 January 2021

Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis

1 reference

7 January 2021

Dimethylfumarate inhibits NF-{kappa}B function at multiple levels to limit airway smooth muscle cell cytokine secretion.

1 reference

7 January 2021

The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells

1 reference

7 January 2021

Dimethylfumarate is a potent inducer of apoptosis in human T cells

1 reference

7 January 2021

Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis

1 reference

7 January 2021

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.

1 reference

7 January 2021

Sp1: emerging roles--beyond constitutive activation of TATA-less housekeeping genes

1 reference

7 January 2021

Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells

1 reference

7 January 2021

Vascular-specific growth factors and blood vessel formation

1 reference

7 January 2021

1 reference

7 January 2021

Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures

21

1 reference

28 November 2024

Identifiers

DOI

10.1038/JID.2011.46

1 reference

1 June 2018

1 reference

1 June 2018